(Q64380702)

2

0 references

W Schmiegel

3

0 references

P C Wu

4

0 references

J Y Lau

Hepatocellular carcinoma: Recent progress

5

0 references

language of work or name

English

0 references

publication date

May 2000

0 references

published in

Journal of Hepatology

0 references

volume

32

0 references

issue

5

0 references

page(s)

771-82

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Therapy of unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Is chemoembolisation of value in inoperable primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Assessment of recombinant adenoviral vectors for hepatic gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

p53 mutations in british patients with hepatocellular carcinoma: clustering in genetic hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Selective extraction of polyoma DNA from infected mouse cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Gain of function mutations in p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Current progress in the gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

The retinoblastoma protein is phosphorylated during specific phases of the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980246-9

7 January 2021